CDMO services speed biologics to clinical trials faster
Complement your long-term biomanufacturing strategy
Deciding when outsourcing makes sense
If your business strategy doesn’t fully align with your organization’s capabilities in terms of expertise, capacity, and resources, it might be wise to consider outsourcing to a biologics CDMO for speed to market.
“To facilitate the speed of clinical process development, we had to assess how this approach would affect our project timeline and then look at strategies to shorten the R&D phase.”
Chris Rode, Scientific Director at Janssen
Pharmaceuticals/Discovery, Product Development & Supply
Choosing the right CDMO
Leveraging service support externally might feel risky when you want to maintain ownership and control over your process outcome, or if you need to protect your intellectual property in new markets. There are five key qualities that you should look for in your CDMO partner, three are sometimes overlooked.
Parallel operations in biopharma manufacturing
Being honest with yourself about what internal capabilities exist and whether the necessary skills and resources are available in-house to deliver on time can help avoid major failures and/or a longer lead time to market.
Read this to decide whether you should double up with a CDMO to reduce risk.
Relationship is everything
Work with a company who fills the gaps in your organization and enhances, rather than replaces, your internal expertise. Ask your CDMO if they offer:
- A one team approach: allowing persons in plant
- Process security: do you trust process details to be shared openly
- Documentation rigor: best practices for optimal communications